



ATTORNEY DOCKET NO. 2003028-0051 (MIT 6834 / Ariad 022 US)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Pomerantz et al.
Serial No.: 08/366,083
Filing Date: December 29, 1994
Title: CHIMERIC TRANSCRIPTION FACTORS

Examiner: McKelvey
Art Unit: 1636

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant requests consideration of this Information Disclosure Statement (IDS).

Type of Statement

The present Information Disclosure Statement is:

- ☐ An *original* Information Disclosure Statement; or
☒ A *supplemental* Information Disclosure Statement.

Certificate of Mailing	
I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450	
September 10, 2004	
Date	Signature
Kathy Hart Gagnon	
Typed or Printed Name of person signing certificate	

Compliance with 37 C.F.R. §1.97

The present Information Disclosure Statement is being filed:

- ☒ Pursuant to 37 C.F.R. § 1.97(b); no fee or certification is required:
 - ☐ Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d);
 - ☐ Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application;
 - ☐ Before the mailing of a first Office action on the merits; or
 - ☒ Before the mailing of a first Office action after the filing of a request for continued examination under § 1.114.

Content of the Information Disclosure Statement

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

- ☒ A copy of each cited reference not indicated with an asterisk is included;
- ☐ Copies of references indicated with an asterisk on the attached form PTO-1449 are not included pursuant to 37 C.F.R. §1.98(d) because they were previously provided to the United States Patent Office in an Information Disclosure Statement that complies with 37 C.F.R. §1.98(a)-(c) and was submitted in the following patent application that is relied upon in the present case for an earlier effective filing date under 35 U.S.C. §120:

Serial Number	Filing Date	Status

- ☐ Copies of English translations of one or more non-English references are included.

Applicant hereby makes the following additional information of record in the above-identified application:

Applicant certifies that the Information Disclosure Statement *either*:

- ☒ Does not contain non-English language citations;
- ☐ Does contain non-English language citations, of which the following is a concise explanation:
- ☐ Includes one or more translations of a non-English citation.

Remarks

The submission of this Information Disclosure Statement should not be construed as a representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56(b).

The submission of this Information Disclosure Statement shall not be construed as a representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. § 102.


It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during the examination of this application; and
3. The citations for the patent(s) and publication(s) be printed on any patent which issues from this application.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).

Respectfully submitted,

Date: September 10, 2004


Brenda Herschbach Jarrell, Ph.D.
Reg. No. 39,223

PATENT DEPARTMENT
CHOATE, HALL & STEWART
Exchange Place
53 State Street
Boston, Massachusetts 02109
Telephone: (617) 248-5000
Facsimile: (617) 248-4000



(REV. 8-83)

U.S. Department of
Commerce
Patent and Trademark OfficeATTY. DOCKET:
2003028-0051
MIT 6834/Ariad 022 USIN RE
APPLICATION NO.:
08/366,083**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**
(Use several sheets if necessary)

APPLICANT: Pomerantz, et al.

FILING DATE:
December 29, 1994GROUP:
1636**U.S. PATENT DOCUMENTS**

Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
	5,283,173	Fields & Song	February 1, 1994		
	5,298,429	Evans et al.	March 29, 1994		
	5,869,337	Crabtree	February 9, 1999		
	6,242,568	Barbas et al.	June 5, 2001		

U.S. PATENT APPLICATIONS

Examiner's Initials:	Serial Number:	Applicant:	Publication Date:	Group:	Art Unit:

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Document No.	Country	Date	Translation	
				Yes	No
	WO 94/18317	PCT	August 18, 1994		

OTHER DOCUMENTS

Examiner's Initials	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)
	Talanian et al. (1990) Science, vol. 249; 769-771
	Deng and Karin (1992) Proc Natl Acad Sci USA, vol. 89; 8572-8576
	Park et al. (1993) Proc Natl Acad Sci USA, vol. 90; 4892-4896
	Park et al. (1995) J Am Chem Soc, vol. 117; 6287-6291
	Park et al. (1996) J Am Chem Soc, vol. 118; 4235-4239
	Attar and Gilman (1992) Mol Cell Biol, vol. 12; 2432-2443
	Chiu et al. (1994) Proc Natl Acad Sci USA, vol. 91; 12574-12578

OTHER DOCUMENTS (Continued)



PTO-1449
(REV. 8-83)

U.S. Department of
Commerce
Patent and Trademark Office

ATTY. DOCKET:
2003028-0051
MIT 6834/Ariad 022 US

IN RE
APPLICATION NO.:
08/366,083

**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**
(Use several sheets if necessary)

APPLICANT: Pomerantz, et al.

FILING DATE:
December 29, 1994

GROUP:
1636

Choo, et al., (1994) Nature, vol.372; 642-645

Choo and Klug (1994) Proc Natl Acad Sci USA, vol.91; 11163-11167

Choo and Klug (1994) Proc Natl Acad Sci USA, vol.91; 11168-11172

Clackson and Wells (1994) Trends Biotech, vol.12; 173-184

Fairall et al., (1993) Nature, vol.366; 483-487

Frankel and Pabo, (1988) Cell, vol.53;675

Grueneberg et al., (1992) Science, vol.257; 1089-1095

Jacobs (1992) EMBO, vol.11; 4507-4517

Klevit (1991) Science, vol.253; 1367-1368

Kordower et al., (1994) Proc Natl Acad Sci USA, vol.91; 10898-10902

Li, et al., (1992) Proc Natl Acad Sci USA, vol.89; 4275-4279

Margolin et al., (1994) Proc Natl Acad Sci USA, vol.91; 4509-4513

Miller et al., (1985) EMBO, vol.4; 1609-1614

Natesan and Gilman (1995) Mol Cell Biol, vol.15; 5975-5982

Pollock and Treisman (1990) Nucleic Acids Research, vol.18; 6197-6204

Pomerantz et al., (1992) Genes & Development, vol.6; 2047-2057


Pomerantz et al., (1995) Proc Natl Acad Sci USA, vol.92; 9752-9756

Pomerantz et al., (1995) Science, vol.267; 93-96

Pomerantz et al., (1995) Keystone Symp. On Gene Therapy and Mole. Medicine, pg. 382;
Abstract C6-232

Rosenfeld (1991) Genes & Development, vol.5; 897-907

OTHER DOCUMENTS (Continued)



PTO-1449

(REV. 8-83)

U.S. Department of
Commerce
Patent and Trademark OfficeATTY. DOCKET:
2003028-0051
MIT 6834/Ariad 022 USIN RE
APPLICATION NO.:
08/366,083**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT***(Use several sheets if necessary)*

APPLICANT: Pomerantz, et al.

FILING DATE:
December 29, 1994GROUP:
1636

Scott et al., (1989) Biochimica et Biophysica Acta, vol.989; 25-48

Sharp et al., (1993) Keystone Symp. On Mole. Biology of Human Pathogenic Viruses, pg. 2;
Abstract M 002

Spencer et al., (1993) Science, vol.262; 1019-1024

Stemmer (1994) Nature, vol.370, 389-390

Sturm et al., (1988) Genes & Development, vol.2; 1582-1599

Thiesen (1995) 24th Ann. Mtg. of Intl. Society for Experimental Hematology, pg. 779;
Abstract 137

Wu et al., (1995) Proc Natl Acad Sci USA, vol.92; 344-348

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.